Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasm Metastasis 2Bulbo-Spinal Atrophy, X-Linked 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Disease 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Bites and Stings 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

enzalutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Hormone-sensitive Prostate Cancer × abiraterone × Clear all
NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Novartis

Phase 2 Recruiting
150 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡